Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03609580 · ClinicalTrials.gov registry record · Phase 1
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
A Phase 1 study of Urinary Retention, sponsored by Hackensack Meridian Health.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
- 1
- Study location
NCT03609580 is a Phase 1 study of Urinary Retention that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 127 participants, roughly in line with the 129-participant average among 11 other Urinary Retention trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT03609580, a Phase 1 study of Urinary Retention, is actively recruiting participants, sponsored by Hackensack Meridian Health.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
- 1
- Study location
Study Summary
Inability to urinate a common complication that happens to many patients after a surgery, especially in men over 60 years of age who undergo surgery on their chest. Urinary retention is uncomfortable, increases anxiety, increases hospital length of stay, and leads to more procedures such as putting in a bladder catheter (Foley). This is uncomfortable, and can lead to bleeding, infection, damage to the urethra and/or bladder and bladder spasm. The goal of this study is to attempt to prevent inability to urinate by giving patients a medication called Flomax (Tamusolin) every day beginning a week before surgery. That medication relaxes the prostate. It's approved by the Food and Drug Administration (FDA) to improve urinary flow in those with enlarged prostates. It is also commonly used in patients with bladder problems due to inability to urinate who have required a Foley.
Conditions Studied
Interventions
- DRUG Tamsulosin - 1 week
- DRUG Tamsulosin - 3 days
Study Locations (1)
New Jersey
- Daniel Mansour - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2026-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03609580
The ClinicalTrials.gov registry entry for NCT03609580 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 129-participant average among 11 other Urinary Retention trials with a reported enrollment target. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urinary Retention appearing as the primary indexed condition, and to 2 interventions - of which Tamsulosin - 1 week is the first listed.
NCT03609580 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT03609580 about?
NCT03609580 is a clinical study titled "Post-operative Urinary Retention (POUR) Following Thoracic Surgery". Inability to urinate a common complication that happens to many patients after a surgery, especially in men over 60 years of age who undergo surgery on their chest. Urinary retention is uncomfortable, increases anxiety, increases hospital length of stay, and leads to more procedures such as putting ...
What is the current status of trial NCT03609580?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2018-05-07. Estimated completion is 2026-03-30.
What conditions does trial NCT03609580 study?
This clinical trial studies the following conditions: Urinary Retention.
What interventions are being tested in trial NCT03609580?
The interventions under investigation include: Tamsulosin - 1 week (DRUG), Tamsulosin - 3 days (DRUG).
Who is sponsoring clinical trial NCT03609580?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03609580 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Retention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery
RECRUITING · Early Phase 1
-
Comparison of Urinary Flow Study
RECRUITING · NA
-
Preoperative Pelvic Floor Physical Therapy to Minimize Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate
RECRUITING · NA
-
How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding
RECRUITING · NA
-
Pelvic Health Electrically Evoked Recording (PEER) 2 Study
RECRUITING · NA
-
Effect of Chlorhexidine Gluconate Bladder Instillations in Patients With Chronic Suprapubic Catheters on Unplanned Healthcare Encounters and Quality of Life
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.